CareDx, Inc. (CDNA) Form 10-Q — Oct 29, 2026
CareDx reported Q3 2026 revenue of $139.4 million, up 39% year over year, with testing services revenue of $119.2 million up 65% and roughly 75,900 tests reported, up 51%. Net income was $19.3 million (diluted EPS $0.35) versus $1.7 million a year ago, with results boosted by $12.5 million of NavDx revenue following the $203.3 million Naveris acquisition, $17.3 million of catch-up revenue on prior-period tests, and an $8.6 million tax benefit from a valuation allowance release.
Key figures
- Eps
- 0.35
- Revenue
- 139362000
- Net Income
- 19292000
- Revenue Yoy
- 39%
- Cash Position
- 250480000
- Shares Outstanding
- 52542786
- Debt
- no debt outstanding
- Goodwill naveris
- $85.7M
- Q3 testing volume
- ~75,900 (+51% YoY)
- Nine month revenue
- $389.0M (+43% YoY)
- Naveris consideration
- $203.3M
- Nine month net income
- $132.7M (vs -$17.2M prior year)
- Nine month diluted eps
- $2.45
- Q3 operating cash flow
- $13M
- Gain on sale lab products
- $113.0M
- Lab products sale proceeds
- $171.7M
- Medicare pct of q3 revenue
- 31%
- Q3 testing services revenue
- $119.2M (+65% YoY)
- Naveris contingent milestones
- up to $100.0M
- Naveris q3 revenue contribution
- $12.5M
- April 2026 repurchase authorization
- $100.0M
- Q3 patient digital solutions revenue
- $20.2M (+31% YoY)
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.